- Revital Amiaz, MD (Psychiatry Department Sheba Medical Center)
The study involves generating neuronal cells from MDD patients to further understand the biological underpinnings of the disorder and establish Genetika+’s MDD disease model.
The study’s overarching aim is to investigate the potential of Genetika+’s blood test to predict treatment outcomes in patients with clinical depression. The study explores the possibility of identifying subgroups of patients with similar biological profiles and utilizing Genetika+’s biological markers to monitor the effectiveness of treatment and predict relapse.
60 subjects with MDD, 20 antidepressant treatment responsive, 20 antidepressant non-responders, and 20 antidepressant differential responders, enrolled in the study.